RSRosemarie E. Schmandt

Rosemarie E. Schmandt

*This is an algorithmically generated author record based on publicly available information.

Rosemarie E. Schmandt has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lean Body Weight and Metformin Are Insufficient to Prevent Endometrial Hyperplasia in Mice Harboring Inactivating Mutations in PTEN

    by David A. Iglesias, Qian Zhang, Joseph Celestino, Charlotte C. Sun, Melinda S. Yates, Rosemarie E. Schmandt, Karen H. Lu

    Objectives: Obesity is a major risk factor for endometrial cancer. We evaluated whether obesity exacerbates progression of endometrial hyperplasia (EH) using the PRCre/+ PTENflox/+ mouse model and examined if the type 2 diabetes drug, metformin, could prevent EH. Methods: Twenty obese (PRCre/+ PTENflox/+) mice were maintained on a high-fat diet, while 20 lean mice ate a matching low-fat diet. Ten mice from each group received metformin (1,000 mg/day) in drinking water. Mice were euthanized at 26 weeks. Uterine tissue was scored for degree of EH. Immunohistochemical staining for Ki67 was used to evaluate cellular proliferation. Markers of PI3K/AKT/mTOR activity were evaluated by immunohistochemistry using activation-specific antibodies. Serum adiponectin was quantified by ELISA. Results: Obesity had no effect on the extent of EH in (PRCre/+ PTENflox/+) mice. While metformin significantly altered circulating adiponectin levels in obese and lean animals, it had no effect on EH. There were no differences in endometrial proliferation as measured by Ki67 staining. Neither obesity nor metformin altered PI3K/AKT/mTOR activity in these animals. Conclusions: Weight and metformin did not affect the severity of EH resulting from PTEN inactivation. Alternative mouse models of early endometrial cancer are required for preclinical cancer prevention studies.


  • The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary

    by Rosemarie E. Schmandt, Marsha Bennett, Stephanie Clifford, Angela Thornton, Feng Jiang, Russell R. Broaddus, Charlotte C. Sun, Karen H. Lu, Anil K. Sood, David M. Gershenson

    Background: We identified the BRK tyrosine kinase in a PCR-based screen of tyrosine kinases expressed by ovarian tumors. BRK expression is restricted to normal differentiating epithelial cells and ...


  • Open Access

    Expression of c‐ABL, c‐KIT, and platelet‐derived growth factor receptor‐β in ovarian serous carcinoma and normal ovarian surface epithelium

    by Rosemarie E. Schmandt, Russell Broaddus, Karen H. Lu, Hyun Shvartsman, Angela Thornton, Anais Malpica, Charlotte Sun, Diane C. Bodurka, David M. Gershenson

    BACKGROUND: Tyrosine kinases, such as c‐KIT, c‐ABL, and platelet‐derived growth factor‐beta (PDGFR‐β), are important regulators of cell growth. Highly potent and selective inhibitors of tyrosine kinases are being investigated as alternatives to standard chemotherapy. One such inhibitor, imatinib mesylate, is being used to treat gastrointestinal stromal tumors and chronic myelogenous leukemia. Ovarian carcinomas frequently develop resistance to conventional chemotherapeutic agents. Immunohistochemical expression of c‐ABL, PDGFR‐β, and c‐KIT was evaluated in ovarian carcinomas to determine whether treatment with imatinib mesylate might be feasible.METHODS: The expression of c‐ABL, c‐KIT, and PDGFR‐β in tumors was evaluated by immunohistochemical analysis of 52 ovarian serous carcinomas, including 21 low‐grade (well differentiated) and 31 high‐grade (poorly differentiated) tumors. Fourteen normal ovaries were also evaluated.RESULTS: In normal ovarian surface epithelium, c‐ABL was expressed universally. PDGFR‐β was expressed in the majority (93%) of samples of normal ovarian epithelium, whereas the c‐KIT protein was undetectable in normal ovarian surface epithelium. Overall, c‐ABL was expressed in 71% of serous carcinomas. c‐ABL was expressed more frequently in the low‐grade serous carcinomas (81%) compared with the high‐grade serous carcinomas (65%). PDGFR‐β expression was observed in 81% of serous carcinomas overall and was observed more frequently in higher‐grade tumors. c‐KIT immunohistochemical staining was absent in low‐grade tumors but was present in 26% of high‐grade serous carcinomas.CONCLUSIONS: The majority of ovarian serous carcinomas express one or more of the kinases targeted by the tyrosine kinase inhibitor, imatinib mesylate, suggesting the potential usefulness of this drug in the treatment of ovarian carcinoma. Cancer 2003;98:758–64. © 2003 American Cancer Society.DOI 10.1002/cncr.11561